Skeletal Complications in Patients with CRPC

  • Takamitsu InoueEmail author
  • Tomonori Habuchi


Skeletal complications in patients with prostate cancer can result in significant morbidity. There is a relatively high prevalence of bone metastasis and reduction of bone mineral density due to androgen deprivation therapy, and together, these can result in the development of multiple skeletal complications in patients with prostate cancer. The relatively long survival (median, 3–4 years) after bone metastases with multiple skeletal complications makes a significant negative impact on patients’ functional status, quality of life, and social resource utilization. To evaluate skeletal complications, the term “skeletal-related events (SREs)” has frequently been used in most randomized trials conducted previously. SREs usually include pathological bone fracture, spinal cord compression, surgery to bone, and radiotherapy to the bone. Recently, symptomatic skeletal events (SSEs), including only symptomatic events, is the recommended term for use in clinical trials. Local therapies for skeletal complications, such as radiation and surgery, are usually performed to reduce local symptoms, such as bone pain or neurological deficits, leading to improvement of the health-related quality of life. Systemic therapies, such as radiopharmaceuticals, bisphosphonates, and monoclonal antibodies against the receptor activator of the nuclear factor-kappa B ligand, are administered to reduce presymptomatic and symptomatic skeletal complications.


Skeletal-related events Symptomatic skeletal events Bone mineral density Pathological bone fracture Spinal cord compression 


  1. 1.
    Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165–76.CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Ottewell PD, Wang N, Meek J, Fowles CA, Croucher PI, Eaton CL, Holen I. Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocr Relat Cancer. 2014;21:769–81.CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Takayama K, Inoue T, Narita S, Maita S, Huang M, Numakura K, Tsuruta H, Saito M, Maeno A, Satoh S, Tsuchiya N, Habuchi T. Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer. Cancer Lett. 2017;397:103–10.CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Vignani F, Bertaglia V, Buttigliero C, Tucci M, Scagliotti GV, Di Maio M. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. Cancer Treat Rev. 2016;44:61–73.CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Clinical Trials Endpoints for the Approval of Cancer Drugs and Biologics, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). 2007.Google Scholar
  6. 6.
    Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B, Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458–68.CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813–22.CrossRefPubMedCentralGoogle Scholar
  8. 8.
    Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Sternberg CN, Efstathiou E, Gagnon DD, Rothman M, Hao Y, Liu CS, Kheoh TS, Haqq CM, Scher HI, de Bono JS. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomized trial. Lancet Oncol. 2012;13:1210–7.CrossRefGoogle Scholar
  9. 9.
    Fizazi K, Scher HI, Miller K, Basch E, Sternberg CN, Cella D, Forer D, Hirmand M, de Bono JS. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomized, phase 3 AFFIRM trial. Lancet Oncol. 2014;15:1147–56.CrossRefGoogle Scholar
  10. 10.
    Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402–18.CrossRefPubMedCentralGoogle Scholar
  11. 11.
    Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O’Bryan-Tear CG, Shan M, Bruland ØS, Parker C. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15:738–46.CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Oster G, Lamerato L, Glass AG, Richert-Boe KE, Lopez A, Chung K, Richhariya A, Dodge T, Wolff GG, Balakumaran A, Edelsberg J. Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer. 2013;21:3279–86.CrossRefPubMedCentralGoogle Scholar
  13. 13.
    Inoue T, Segawa T, Kamba T, Yoshimura K, Nakamura E, Nishiyama H, Ito N, Kamoto T, Habuchi T, Ogawa O. Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan. Urology. 2009;73:1104–9.CrossRefPubMedCentralGoogle Scholar
  14. 14.
    Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563–72.CrossRefPubMedCentralGoogle Scholar
  15. 15.
    Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8:98–101.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Esposito M, Kang Y. Targeting tumor-stromal interactions in bone metastasis. Pharmacol Ther. 2014;141:222–33.CrossRefPubMedCentralGoogle Scholar
  17. 17.
    Nieswandt B, Hafner M, Echtenacher B, Männel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999;59:1295–300.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11:411–25.CrossRefPubMedCentralGoogle Scholar
  19. 19.
    Sun YX, Wang J, Shelburne CE, Lopatin DE, Chinnaiyan AM, Rubin MA, Pienta KJ, Taichman RS. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem. 2003;89:462–73.CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Sun YX, Fang M, Wang J, Cooper CR, Pienta KJ, Taichman RS. Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate. 2007;67:61–73.CrossRefPubMedCentralGoogle Scholar
  21. 21.
    Schneider JG, Amend SR, Weilbaecher KN. Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. Bone. 2011;48:54–65.CrossRefPubMedCentralGoogle Scholar
  22. 22.
    Sethi N, Dai X, Winter CG, Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 2011;19:192–205.CrossRefPubMedCentralGoogle Scholar
  23. 23.
    Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655–64.CrossRefPubMedCentralGoogle Scholar
  24. 24.
    Brubaker KD, Vessella RL, True LD, Thomas R, Corey E. Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res. 2003;18:222–30.CrossRefPubMedCentralGoogle Scholar
  25. 25.
    Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsbrun M. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem. 1986;261:1266574.Google Scholar
  26. 26.
    Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584–93.CrossRefPubMedCentralGoogle Scholar
  27. 27.
    Reddington JA, Mendez GA, Ching A, Kubicky CD, Klimo P Jr, Ragel BT. Imaging characteristic analysis of metastatic spine lesions from breast, prostate, lung, and renal cell carcinomas for surgical planning: osteolytic versus osteoblastic. Surg Neurol Int. 2016;7:S361–5.CrossRefPubMedCentralGoogle Scholar
  28. 28.
    Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, Pratap J, Keller E, Stein GS, Lian JB. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene. 2010;29:811–21.CrossRefPubMedCentralGoogle Scholar
  29. 29.
    Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995;1(9):944.CrossRefPubMedCentralGoogle Scholar
  30. 30.
    Yin JJ, Mohammad KS, Käkönen SM, Harris S, Wu-Wong JR, Wessale JL, Padley RJ, Garrett IR, Chirgwin JM, Guise TA. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A. 2003;100:10954–9.CrossRefPubMedCentralGoogle Scholar
  31. 31.
    Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA, Sleep DJ, Isaacson JD, Nelson JB, Atrasentan Phase III Study Group Institutions. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007;110:1959–66.CrossRefPubMedCentralGoogle Scholar
  32. 32.
    Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology. 2007;69:500–4.CrossRefPubMedCentralGoogle Scholar
  33. 33.
    Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90:6410–7.CrossRefPubMedCentralGoogle Scholar
  34. 34.
    Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol. 2006;175:1679–83.CrossRefPubMedCentralGoogle Scholar
  35. 35.
    Colvard DS, Eriksen EF, Keeting PE, Wilson EM, Lubahn DB, French FS, Riggs BL, Spelsberg TC. Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci U S A. 1989;86:854–7.CrossRefPubMedCentralGoogle Scholar
  36. 36.
    Russell PK, Clarke MV, Skinner JP, Pang TP, Zajac JD, Davey RA. Identification of gene pathways altered by deletion of the androgen receptor specifically in mineralizing osteoblasts and osteocytes in mice. J Mol Endocrinol. 2012;49:1–10.CrossRefPubMedCentralGoogle Scholar
  37. 37.
    Wiren KM, Zhang XW, Toombs AR, Kasparcova V, Gentile MA, Harada S, Jepsen KJ. Targeted overexpression of androgen receptor in osteoblasts: unexpected complex bone phenotype in growing animals. Endocrinology. 2004;145:3507–22.CrossRefPubMedCentralGoogle Scholar
  38. 38.
    Proell V, Xu H, Schüler C, Weber K, Hofbauer LC, Erben RG. Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats. Bone. 2009;45:677–81.CrossRefPubMedCentralGoogle Scholar
  39. 39.
    Li X, Ominsky MS, Stolina M, Warmington KS, Geng Z, Niu QT, Asuncion FJ, Tan HL, Grisanti M, Dwyer D, Adamu S. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Bone. 2009;45:669–76.CrossRefPubMedCentralGoogle Scholar
  40. 40.
    Kawano H, Sato T, Yamada T, Matsumoto T, Sekine K, Watanabe T, Nakamura T, Fukuda T, Yoshimura K, Yoshizawa T, Aihara K, Yamamoto Y, Nakamichi Y, Metzger D, Chambon P, Nakamura K, Kawaguchi H, Kato S. Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci U S A. 2003;100:9416–21.CrossRefPubMedCentralGoogle Scholar
  41. 41.
    Humphrey EL, Williams JH, Davie MW, Marshall MJ. Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. Bone. 2006;38:652–61.CrossRefPubMedCentralGoogle Scholar
  42. 42.
    Swanson C, Lorentzon M, Conaway HH, Lerner UH. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones. Endocrinology. 2006;147:3613–22.CrossRefPubMedCentralGoogle Scholar
  43. 43.
    Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110:1860–7.CrossRefPubMedCentralGoogle Scholar
  44. 44.
    DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer. 2007;15:869–76.CrossRefPubMedCentralGoogle Scholar
  45. 45.
    Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, Schulman KA. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol. 2005;16:579–84.CrossRefPubMedCentralGoogle Scholar
  46. 46.
    Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications. J Urol. 2007;178:1423–8.CrossRefPubMedCentralGoogle Scholar
  47. 47.
    Hagiwara M, Delea TE, Saville MW, Chung K. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis. 2013;16:23–7.CrossRefPubMedCentralGoogle Scholar
  48. 48.
    Lage MJ, Barber BL, Harrison DJ, Jun S. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care. 2008;14:317–22.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Hechmati G, Cure S, Gouépo A, Hoefeler H, Lorusso V, Lüftner D, Duran I, Garzon-Rodriguez C, Ashcroft J, Wei R, Ghelani P, Bahl A. Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study. J Med Econ. 2013;16:691–700.CrossRefPubMedCentralGoogle Scholar
  50. 50.
    Aass N, Fosså SD. Pre- and post-treatment daily life function in patients with hormone resistant prostate carcinoma treated with radiotherapy for spinal cord compression. Radiother Oncol. 2005;74:259–65.CrossRefPubMedCentralGoogle Scholar
  51. 51.
    Rades D, Stalpers LJ, Veninga T, Rudat V, Schulte R, Hoskin PJ. Evaluation of functional outcome and local control after radiotherapy for metastatic spinal cord compression in patients with prostate cancer. J Urol. 2006;175:552–6.CrossRefPubMedCentralGoogle Scholar
  52. 52.
    Crnalic S, Hildingsson C, Wikström P, Bergh A, Löfvenberg R, Widmark A. Outcome after surgery for metastatic spinal cord compression in 54 patients with prostate cancer. Acta Orthop. 2012;83:80–6.CrossRefPubMedCentralGoogle Scholar
  53. 53.
    Shoskes DA, Perrin RG. The role of surgical management for symptomatic spinal cord compression in patients with metastatic prostate cancer. J Urol. 1989;142:337–9.CrossRefPubMedCentralGoogle Scholar
  54. 54.
    Williams BJ, Fox BD, Sciubba DM, Suki D, Tu SM, Kuban D, Gokaslan ZL, Rhines LD, Rao G. Surgical management of prostate cancer metastatic to the spine. J Neurosurg Spine. 2009;10:414–22.CrossRefPubMedCentralGoogle Scholar
  55. 55.
    Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, Porter AT, Zivanovic MA. A prospective, randomized double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer. 1991;27:954–8.CrossRefPubMedCentralGoogle Scholar
  56. 56.
    Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, Bertrand A, Ahmann FR, Orihuela E, Reid RH, Lerski RA, Collier BD, McKillop JH, Purnell GL, Pecking AP, Thomas FD, Harrison KA. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16:1574–81.CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of UrologyAkita University Graduate School of MedicineAkitaJapan

Personalised recommendations